目的 分析慢性阻塞性肺疾病急性加重期(AECOPD)和AECOPD合并支气管扩张(BE)的临床特征,探讨血小板计数在预测AECOPD合并BE的价值。方法 回顾性分析2021至2023年在武警重庆总队医院就诊的AECOPD患者临床资料,其中AECOPD患者为对照组(AECOPD组),AECOPD合并BE的患者为病例组(AECOPD-BE组),对两组的基本情况和临床指标差异进行比较,分析AECOPD合并BE的影响因素。结果 共纳入470例AECOPD患者,59例合并BE(12.55%)。AECOPD-BE组的血小板平均水平为[228.00(182.00,279.00)]×109/L,高于AECOPD组平均水平[197.00(154.00,237.75)]×109/L,差异有统计学意义(Z=-3.731,P＜0.001)。多因素logistic分析发现,高血小板计数(OR=1.003,95%CI:1.001~1.006)是 AECOPD合并BE的危险因素,曲线下面积为0.651(P<0.05)。结论 高血小板计数是AECOPD合并BE的危险因素,对于COPD合并BE的患者具有一定的预测价值。
Abstract
Objective To analyze the clinical features of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and AECOPD complicated with bronchiectasis (BE) and to explore the value of platelet count in predicting AECOPD combined with BE (AECOPD-BE). Methods A retrospective analysis was conducted to collect the clinical data of AECOPD patients who visited Chongqing Municipal Corps Hospital of Chinese People’s Armed Police Force from 2021 to 2023. The patients with AECOPD were assigned to the control group (AECOPD group), while those with AECOPD-BE were assigned to the case group (AECOPD-BE group). The basic conditions and clinical indicators were compared between the two groups and the influencing factors of AECOPD combined with BE were analyzed. Results A total of 470 AECOPD patients were included and 59 patients (12.55%) had BE. The average platelet count of the AECOPD-BE group 228.00 (182.00, 279.00)]×109/L] was significantly higher than that of the AECOPD group [197.00 (154.00, 237.75)×109/L], and the difference was statistically significant (Z=-3.731, P<0.001). Multivariate logistic regression analysis revealed that elevated platelet count (OR=1.003, 95% CI: 1.001-1.006) was a risk factor for AECOPD-BE, with an area under the curve of 0.651 (P<0.05). Conclusions Elevated platelet count is a risk factor for AECOPD combined with BE, which has certain predictive value in AECOPD-BE patients.
关键词
慢性阻塞性肺疾病急性加重期 /
支气管扩张 /
合并症 /
血小板计数 /
影响因素
Key words
acute exacerbation of chronic obstructive pulmonary disease /
bronchiectasis /
comorbidity /
platelet count /
influencing factors
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Ma L, Huo X, Yang A, et al. Metal Exposure, smoking, and the risk of COPD: a nested case-control study in a chinese occupational population[J]. Int J Environ Res Public Health, 2022, 19(17):10896.
[2] 胡晓飞, 陈 洁, 马 飞, 等. 慢性阻塞性肺疾病患者合并支气管扩张的临床特征及相关因素分析[J]. 浙江医学, 2024, 46(17):1868-1871.
[3] Li T, Chen L, Xu H, et al. The association between cardiovascular diseases and their subcategories with the severity of chronic obstructive pulmonary disease: a large cross-sectional study based on a Chinese hospital population cohort[J]. Front Cardiovasc Med, 2025, 12:1502205.
[4] 魏玲玲, 黄黎黎, 曹 艳. 2016-2020年武汉市硚口区慢性阻塞性肺疾病患者合并支气管扩张症及影响因素[J]. 公共卫生与预防医学, 2023, 34(1):117-119,151.
[5] 白英连, 张旗松, 万 军, 等. 慢性阻塞性肺疾病合并支气管扩张的临床特点分析[J]. 中国医药科学, 2018, 8(21):165-167,191.
[6] Sehgal I S, Dhooria S, Agarwal R. Chronic obstructive pulmonary disease and malnutrition in developing countries[J]. Curr Opin Pulm Med, 2017, 23(2):139-148.
[7] 邹外龙, 闫 磊, 张 鑫, 等. 支气管扩张症合并慢性阻塞性肺疾病急性加重患者住院死亡的相关因素[J]. 中华老年多器官疾病杂志, 2021, 20(8):590-594.
[8] 周楚君, 李倬哲, 王 琴, 等. 成人支气管扩张症预后影响因素分析[J]. 中国临床医学, 2023, 30(4):628-635.
[9] 叶梓楠, 杨 婕, 胡建武, 等. 慢性阻塞性肺疾病合并支气管扩张患者的临床特征和高危因素分析[J]. 临床肺科杂志, 2024, 29(9):1330-1335.
[10] 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 中国慢性阻塞性肺疾病基层诊疗与管理指南(2024年)[J]. 中华全科医师杂志, 2024, 23(6):578-602.
[11] 成人支气管扩张症诊治专家共识编写组. 成人支气管扩张症诊治专家共识[J]. 中华结核和呼吸杂志, 2012, 35(7):485-492.
[12] 熊华利, 舒 强, 邱建平, 等. 不同生命周期饥荒暴露与成年期中心性肥胖的相关性分析[J]. 公共卫生与预防医学, 2023, 34(4):39-43.
[13] 彭惠忠, 连金诗. 慢性阻塞性肺疾病并发心血管疾病的影响因素分析[J]. 浙江实用医学, 2024, 29(6):488-489.
[14] 杜 飞, 张 李, 陈代刚, 等. 不同程度的慢性阻塞性肺疾病患者合并心血管疾病及其危险因素的比较[J]. 中国呼吸与危重监护杂志, 2017, 16(4):311-313.
[15] 陈 霄, 史 娟, 唐幼玲. 慢性阻塞性肺疾病患者合并支气管扩张的相关影响因素模型构建及其预防措施分析[J]. 湖北科技学院学报(医学版), 2024, 38(1):43-47.
[16] Dai Z, Zhong Y, Cui Y, et al. Analysis of clinical characteristics, prognosis and influencing factors in patients with bronchiectasis-chronic obstructive pulmonary disease overlap syndrome: a prospective study for more than five years[J]. J Glob health, 2024, 14:04129.
[17] Fawzy A, Anderson J A, Cowans N J, et al. Association of platelet count with all-cause mortality and risk of cardiovascular and respiratory morbidity in stable COPD[J]. Respir Res, 2019, 20(1):86.
[18] Malerba M, Olivini A, Radaeli A, et al. Platelet activation and cardiovascular comorbidities in patients with chronic obstructive pulmonary disease[J]. Curr Med Res Opin, 2016, 32(5):885-891.
[19] Harrison M T, Short P, Williamson P A, et al. Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy?[J]. Thorax, 2014, 69(7):609-615.
[20] Kara Z M Y, Yagci S, Ozkarafakili M A, et al. Relationship between platelet parameters and eosinophils with disease severity, CRP and treatment in stable COPD[J]. Sisli Etfal Hastan Tip Bul, 2024, 58(2):171-178.
[21] Ulasli S S, Ozyurek B A, Yilmaz E B, et al. Mean platelet volume as an inflammatory marker in acute exacerbation of chronic obstructive pulmonary disease[J]. Pol Arch Med Wewn, 2012, 122(6):284-290.
[22] Aliberti S, Sotgiu G, Gramegna A, et al. Thrombocytosis during stable state predicts mortality in bronchiectasis[J].Ann Am Thorac Soc, 2021, 18(8):1316-1325.
[23] Gao F, He S, Li J, et al. The Association between systemic immune-inflammation index at admission and readmission in patients with bronchiectasis[J]. J Inflamm Res, 2024, 17:6051-6061.
[24] Lei C, Zeng Z, Chen F, et al. Eosinophilic bronchiectasis increases length and cost of hospitalization: a retrospective analysis in a hospital of southern China from 2012 to 2020[J]. BMC Pulm Med, 2024, 24(1):98.
[25] 梁乐诗, 莫环琦, 张 弋, 等. 血小板与慢性阻塞性肺疾病相关研究进展[J]. 中华结核和呼吸杂志, 2022, 45(10):1050-1054.
PDF(1086 KB)
